Aquila BioMedical, a niche preclinical contract research organization (CRO), has expanded its laboratory space and capabilities in response to growing demand for its specialist immuno-oncology and histology services. Since forming in 2011, the CRO has built a strong reputation for supporting biotech and pharmaceutical companies’ early drug development programs through offering specialized assays to investigate therapeutic manipulation of immune cell function. The success of Aquila’s immuno...